Kaldor John M, Guy Rebecca J, Wilson David
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia.
Curr Opin HIV AIDS. 2008 Jul;3(4):504-8. doi: 10.1097/COH.0b013e32830413dc.
The aim of this article is to outline key challenges facing the conduct of efficacy trials for biomedical strategies to prevent HIV infection.
The past 2-3 years have seen tumultuous development in this field. There have been disappointing findings in efficacy trials of vaginal microbicides, vaccines, the diaphragm and suppressive therapy for herpes, but a major breakthrough with the evidence that male circumcision prevents acquisition of infection. Meanwhile, clarity has started to emerge on a number of issues regarding trial conduct, including provision of standard of care, involvement of communities, and preparation for implementing effective interventions.
HIV prevention practice must continue to rely on condom promotion and other established strategies while biomedical approaches continue to be assessed and their implementation strategies evolve.
本文旨在概述生物医学策略预防HIV感染的疗效试验所面临的主要挑战。
在过去两到三年中,该领域发展动荡。阴道杀菌剂、疫苗、子宫托以及疱疹抑制疗法的疗效试验结果令人失望,但男性包皮环切术可预防感染这一证据带来了重大突破。与此同时,在试验实施的一些问题上开始有了清晰的认识,包括提供标准治疗、社区参与以及实施有效干预措施的准备工作。
在生物医学方法持续接受评估且其实施策略不断演变的同时,HIV预防实践必须继续依赖于推广使用避孕套及其他既定策略。